OncoZenge AB (publ) (STO:ONCOZ)

Market Cap	101.01M +92.7%
Revenue (ttm)	2.78M +278,300.0%
Net Income	-15.94M
EPS	-1.31
Shares Out	14.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,034
Average Volume	30,748
Open	7.00
Previous Close	7.19
Day's Range	6.63 - 7.50
52-Week Range	4.52 - 10.28
Beta	1.33
RSI	69.36
Earnings Date	Apr 30, 2026

About OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ONCOZ

Financial Performance

In 2025, OncoZenge AB's revenue was 2.78 million, an increase of 278300.00% compared to the previous year's 1,000. Losses were -15.94 million, 83.5% more than in 2024.